Long acting GLP-1 receptor agonist (injectable)
Exenatide (ITCA 650 implant) 40 µg implant continuous
EXENIMP_IMPLANT_40UG_CONT
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.38 (0.01 to 14.53) | 0.65 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.03 (2.32 to 11.03) | 0.25 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.97 (1.85 to 21.45) | 0.26 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.45 (1.00 to 14.13) | 0.23 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.66 (0.80 to 32.08) | 0.20 |